Many are called, yet few are chosen. Are neuropsychiatric clinical trials letting us down?

Drug Discovery Today

Volumn 16, Issue 5-6, 2011, Pages 173-175

  McArthur, Robert ^a  

^a McArthur and Associates   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; AMYLOID; AMYLOID PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; DIMEBON; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NEUROKININ 1 RECEPTOR ANTAGONIST; PLACEBO; SEMAGACESTAT; TACRINE; VERUCERFONT;

ALZHEIMER DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEPRESSION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOTHERAPY; MAJOR DEPRESSION; MENTAL DISEASE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION;

EID: 79952449643     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.12.005     Document Type: Editorial

References (16)

1. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder (2010) (http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol- newsArticle&id=1471129 )
2. Pfizer and Medivation Announce Results from Two Phase 3 Studies in Dimebon (Latrepirdine*) Alzheimer's Disease Clinical Development Program (2010) (http://www.pfizer.com/news/press-releases/pfizer-press-releases.jsp )
3. A.D. Roses, and M.N. Pangalos Drug development and Alzheimer disease Am. J. Geriatr. Psychiatry 11 2 2003 123 130 (Pubitemid 36254186)
4. M.D. Lindner Development, optimization and use of preclinical behavioral models to maximise the productivity of drug discovery for Alzheimer's disease R.A. McArthur, F. Borsini, Animal and Translational Models for CNS Drug Discovery: Neurologic Disorders, 2 2008 Academic Press/Elsevier New York 93 157
5. Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials (2010) (http://www.newsroom. lilly.com/releasedetail.cfm?ReleaseID=499794 )
6. J.M. Orgogozo Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 1 2003 46 54
7. S. Röskam APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks Neurosci. Biobehav. Rev. 34 4 2010 487 499
8. C. Hock Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 4 2003 547 554 (Pubitemid 36645030)
9. C. Holmes Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372 9634 2008 216 223 (Pubitemid 351978111)
10. L.S. Schneider Issues in design and conduct of clinical trials for cognitive-enhancing drugs R.A. McArthur, F. Borsini, Animal and Translational Models for CNS Drug Discovery: Neurologic Disorders, 2 2008 Academic Press/Elsevier New York 21 76
11. J.P. McEvoy, and Freudenreich O Issues in the design and conductance of clinical trials R.A. McArthur, F. Borsini, Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders, 1 2008 Academic Press San Diego 75 95
12. L.S. Schneider, and M. Sano Current Alzheimer's disease clinical trials: methods and placebo outcomes Alzheimers Dement 5 5 2009 388 397
13. N. Engelhardt Rating the raters: assessing the quality of Hamilton rating scale for depression clinical interviews in two industry-sponsored clinical drug trials J. Clin. Psychopharmacol. 26 1 2006 71 74 (Pubitemid 43167094)
14. R.E. Becker Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J. Alzheimers Dis. 15 2 2008 303 325
15. R.A. McArthur The value of animal models for predicting CNS therapeutic action G. Koob, M. Le Moal, R. Thompson, Encyclopedia of Behavioral Neuroscience, 3 2010 Academic Press Oxford 436 444
16. R.A. McArthur Cognitive effects of muscarinic M1 functional agonists in nonhuman primates and in clinical trials Curr. Opin. Investig. Drugs 11 7 2010 740 760